Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity

Clinical Cancer Research

Volumn 14, Issue 12, 2008, Pages 3896-3905

  Sittler, Taylor ^a   Zhou, Jun ^b   Park, Joosang ^b   Yuen, Noah K ^e   Sarantopoulos, Stefanie ^b   Mollick, Joseph ^f   Salgia, Ravi ^g   Giobbie Hurder, Anita ^c   Dranoff, Glenn ^b,d   Hodi, F Stephen ^b,c,d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF HAWAII   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; COMPLEMENTARY DNA; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; CANCER VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; CANCER PATIENT; CELL CYCLE REGULATION; CELL INFILTRATION; CONTROLLED STUDY; DNA LIBRARY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY; VACCINATION; ANTIBODY PRODUCTION; CELL CULTURE; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANTIBODY FORMATION; AUTOANTIGENS; AUTOIMMUNITY; CANCER VACCINES; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 52449091657     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4782     Document Type: Article

References (47)

1. Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994;264:713-6.
2. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
3. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony- stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 1998;95:13141-6.
4. Li G, Miles A, Line A, Rees RC. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 2004;53:139-43.
5. Jager D. Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). Methods Mol Biol 2007;360:319-26.
6. Salgia R, Lynch X Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma J Clin Oncol 2003;21:624-30.
7. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003;21:3343-50.
8. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997;3: 342-9.
9. Mollick J, Hodi F, Soiffer R, Nadler L, Dranoff G. MUCI-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun 2003;3.
10. Hodi FS, Schmollinger JC, Soiffer RJ, et al. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction Proc Natl Acad Sci US A 2002;99:6919-24.
11. Schmollinger JC, Vonderheide RH, Hoar KM, et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A 2003;100:3398-403.
12. Ochs RL, Lischwe MA, Shen E, Carroll RE, Busch H Nucleologenesis: composition and fate of prenu- cleolar bodies. Chromosoma 1985:92:330-6.
13. Derenzini M, Trere D, Pession A, Montanaro L, Sirri V, Ochs RL. Nucleolar function and size in cancer cells. Am J Pathol 1998;152:1291-7.
14. Codony-Servat J, Gimeno R, Gelpi C, Rodriguez- Sanchez JL, Juarez C. The two isoforms of the 90-kDalton nucleolus organizer region autoantigen (upstream binding factor) bind with different avidity to DNA modified by the antitumor drug cisplatin. Biochem Pharmacol 1996;51:1131-6.
15. Huang R.WuT, Xu L, Liu A, Ji Y, Hu G. Upstream binding factor up-regulated in hepatocellular carcinoma is related to the survival and cisplatin-sensitivity of cancer cells. FASEB J 2002;16:293-301.
16. Zhai X, Beckmann H, Jantzen HM, Essigmann JM. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Biochemistry 1998;37:16307-15.
17. Rodriguez-Sanchez JL, Gelpi C, Juarez C, Hardin JA. Anti-NOR 90. A new autoantibody in scleroderma that recognizes a 90-kDa component of the nucleo- lus-organizing region of chromatin. J Immunol 1987;139:2579-84.
18. Chan EK, Imai H, Hamel JCTan EM. Human autoantibody to RNA polymerase I transcription factor hUBF. Molecular identity of nucleolus organizer region autoantigen NOR-90 and ribosomal RNA transcription upstream binding factor. J Exp Med 1991;174:1239-44.
19. Fujii T, Mimori T, Akizuki M. Detection of autoantibodies to nucleolar transcription factor NOR 90/hUBF in sera of patients with rheumatic diseases, by recombinant autoantigen-based assays. Arthritis Rheum 1996;39:1313-8.
20. Dick T, Mierau R, Sternfeld R.Weiner EM, Genth E. Clinical relevance and HLA association of autoantibodies against the nucleolus organizer region (NOR- 90). J Rheumatol 1995;22:67-72.
21. van Nimwegen MJ, van de Water B. Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol 2007;73:597-609.
22. Mon NN, Ito S, SengaT, Hamaguchi M. FAK signaling in neoplastic disorders: a linkage between inflam-mation and cancer. Ann N Y Acad Sci 2006;1086:199-212
23. Hess AR, Postovit LM, Margaryan NV, et al Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 2005,65:9851-60.
24. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream Cell 2007;129:1261-74.
25. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinico- pathologic study of 292 cases. J Clin Oncol 2005;23:1473-82.
26. Lasorella A, Uo T, lavarone A, Id proteins at the cross-road of development and cancer. Oncogene 2001;20:8326-33.
27. Wong YC, Wang X, Ling MT ld-1 expression and cell survival. Apoptosis 2004;9:279-89.
28. Cheung HW, Ling MT.Tsao SW, Wong YC, Wang X ld-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 2004;25:881-7
29. Ryu B, Kim DS, Deluca AM, et al Id1 expression is transcriptionally regulated in radial growth phase melanomas. Int J Cancer 2007;121:1705-9.
30. Lee TK, Poon RT, Yuen AP, et al. Regulation of angiogenesis by ld-1 through hypoxia-inducible factor-1 a-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma Clin Cancer Res 2006;12:6910-9.
31. Di K, Ling MT.Tsao SW, Wong YC, Wang X ld-1 modulates senescence andTGF-β1 sensitivity in prostate epithelial cells. Biol Cell 2006;98:523-33.
32. Fensterle J, Becker JC, Potapenko T, et al. B-Raf specific antibody responses in melanoma patients. BMC Cancer 2004;4:62.
33. Sharkey MS, Lizee G, Gonzales Ml, Patel S.Topalian SL. CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation-Cancer Res 2004;64:1595-9
34. Andersen MH, Fensterle J, Ugurel S, et al Immuno-genicity of constitutively active V599EBRaf Cancer Res 2004;64:5456-60.
35. Whitehouse JM, Holborow EJ. Smooth muscle antibody in malignant disease. Br Med J 1971;4:511-3.
36. Wasserman J, Glas U, Blomgren H. Autoantibodies in patients with carcinoma of the breast. Correlation with prognosis Clin Exp Immunol 1975;19:417-22.
37. Hodson ME, Turner-Warwick M. Autoantibodies in patients with bronchial carcinoma. Thorax 1975;30:367-70.
38. Imai H, NakanoY Kiyosawa K.Tan EM. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer 1993;71:26-35.
39. Imai H, Ochs Rl, Kiyosawa K, Furuta S, Nakamura RM.Tan EM. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 1992;140:859-70.
40. Imai H, Kiyosawa K, Chan EK.Tan EM. Autoantibodies in viral hepatitis-related hepatocellular carcinoma. Intervirology 1993;35:73-85.
41. Winter SF, Sekido Y, Minna JD, et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer lnst 1993;85:2012-8.
42. Gogas H, loannovich J, Dafni U, etal. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
43. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7.
44. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53.
45. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxicT- lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741-50.
46. Ji Q, Gondek D, Hurwitz AA. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response. J Immunol 2005;175:1456-63.
47. Kawakami Y, Sumimoto H, Fujita T, Matsuzaki Y. Immunological detection of altered signaling molecules involved in melanoma development. Cancer Metastasis Rev 2005;24:357-66.